Bridging together signals generated at the cross-road between BC cells and the intra-tumor vascular niche, S100A7 may be regarded as a novel therapeutic target for a clear-cut manipulation of the tumor microenvironment toward better clinical outcomes of BC patients, especially when affected by disorders associated with de-regulated IGF-1/IGF-1R pathway. This evidence concerns the gene S100A7 and breast cancer.